1. McGuire WP: Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J Clin Onco. 2009, 27: 4633-4634. 10.1200/JCO.2009.23.6653.
2. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study Cancer. 1986, 57 (9): 1725-1730.
3. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, ICBP Module 1 Working Group: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011, 377 (9760): 127-38. 10.1016/S0140-6736(10)62231-3.
4. Seidman JD, Russel P, Kurman RJ: Surface epithelial tumors of the ovary, (Chapter 18). In Blaustein’s Pathology of the Female Genital Tract. Edited by: Kurman RJ. 2002, New York: Springer, 791-904. 5
5. Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI, Hauptmann S, Rutgers J: WHO Histological Classification of Tumours of the ovary (Chapter 2). In Pathology and Genetics of Tumours of the Breast and Female Genital organs. Edited by: Tavassoli FA, Devilee P. 2003, Lyon: IARC Pres, 113-161.